Macular Edema News and Research

RSS

Laser therapy more effective than corticosteroids in long term treatment of diabetic macular edema

A promising new drug therapy used to treat abnormal swelling in the eye - a condition called diabetic macular edema - proved less effective than traditional laser treatments in a study funded by the National Eye Institute (NEI), part of the National Institutes of Health (NIH).

29 Jul 2008

Ranibizumab therapy for diabetic eye disease shows promise

A JDRF collaboration between Johns Hopkins researchers and Genentech has shown that a drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery.

29 Apr 2008

Age Intervention Eyelash products seized by U.S. Marshals

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized today 12,682 applicator tubes of Age Intervention Eyelash, a product that may, in some users, lead to decreased vision.

19 Nov 2007

Eyelash growth product can damage vision

American consumers are being warned by the Food and Drug Administration (FDA) about the dangers of a product which promises to increase eyelash growth.

19 Nov 2007

Age-related macular degeneration patient receives investigational eye drops

An 88-year-old man at The Methodist Hospital in Houston is one of two patients in the world today to receive an investigational eye drop that may restore sight for those suffering from neovascular (wet) age-related macular degeneration, a major cause of central visual loss and one of the leading causes of blindness in people over 60 in the United States.

17 Aug 2007

Clinical trial of Ranibizumab for edema of the mAcula in diabetes

The Juvenile Diabetes Research Foundation, the world's largest charitable funder of type 1 diabetes research, announced that the Ranibizumab for Edema of the mAcula in Diabetes Phase 2 Study (READ 2) is now enrolling patients.

2 Apr 2007

New compound ruboxistaurin may decrease vision loss in diabete

A multicenter international study chaired by a Joslin Diabetes Center investigator and reported in the July issue of the American Diabetes Association's journal Diabetes brings hopeful news to the 18 million people in the United States -- and millions more worldwide -- with type 1 or type 2 diabetes.

15 Jul 2005

New treatment improves visual acuity score of patients with retinitis pigmentosa

Neurotech SA announced positive results from an open-label Phase I clinical trial (03-EI-0234) of its lead product, NT-501. NT-501 uses Neurotech’s patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF) to eyes of visually impaired patients with retinitis pigmentosa (RP). Neurotech is a biotechnology company specializing in the development of novel therapeutics to treat diseases of the eye. The company is headquartered in Paris.

8 May 2005

Ruboxistaurin may reduce vision loss from diabetes-induced eye disease

Eli Lilly and Company's investigational compound ruboxistaurin may reduce vision loss from diabetes-induced eye disease, according to new analyses of previously reported data presented at the 2004 Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology in New Orleans, La.

26 Oct 2004

Herbal, nutritional supplements linked to side effects ranging from dry eye to retinal hemorrhages and transient visual loss

An estimated 42 percent of Americans use herbal medicines or nutritional supplements. Many people taking these products and their physicians are unaware of the adverse reactions they can cause.

13 Oct 2004

Findings about diabetic eye disease may lead to improved screenings and treatment for people with diabetes

Eli Lilly and Company have announced key findings from analyses of prior study data that enhances understanding of vision loss due to diabetic retinopathy, a diabetic microvascular complication that affects an estimated 50 million people worldwide.

10 Sep 2004

Latinos living in the United States have high rates of eye disease and visual impairment

Researchers found that Latinos had high rates of diabetic retinopathy, an eye complication of diabetes; and open-angle glaucoma, a disease that damages the optic nerve.

9 Aug 2004

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema

In a study of five diabetic patients with persistent macular edema, breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula and, in some cases, improved visual acuity. Researchers think the therapy could be used in conjunction with laser treatments that also improve oxygenation in the retina to provide long-term stability in these patients.

20 May 2004

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema, fluid buildup in the part of the eye responsible for central vision, according to a pilot study by scientists at Johns Hopkins and the National Eye Institute.

18 May 2004

Risk Assessment of Diabetic Retiopathy Improved by Screening Methods

Eli Lilly and Company as part of a continued commitment to innovation in the area of diabetes, announced today the creation of a strategic relationship with EyeTel Imaging, Inc. to improve screening and detection of diabetic retinopathy, one of the potentially devastating diabetic microvascular complications. The agreement, which expands the relationship between the two companies, will provide EyeTel with on-going operational support from Lilly, allowing EyeTel to provide primary care physicians access to state-of-the-art patient risk assessment tools and education programs.

23 Mar 2004

Macular Edema News and Research

Laser therapy more effective than corticosteroids in long term treatment of diabetic macular edema

Ranibizumab therapy for diabetic eye disease shows promise

Age Intervention Eyelash products seized by U.S. Marshals

Eyelash growth product can damage vision

Age-related macular degeneration patient receives investigational eye drops

Clinical trial of Ranibizumab for edema of the mAcula in diabetes

New compound ruboxistaurin may decrease vision loss in diabete

New treatment improves visual acuity score of patients with retinitis pigmentosa

Ruboxistaurin may reduce vision loss from diabetes-induced eye disease

Herbal, nutritional supplements linked to side effects ranging from dry eye to retinal hemorrhages and transient visual loss

Findings about diabetic eye disease may lead to improved screenings and treatment for people with diabetes

Latinos living in the United States have high rates of eye disease and visual impairment

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema

Risk Assessment of Diabetic Retiopathy Improved by Screening Methods

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News